spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Wellcome Trust Centre for Human Genetics and Genomics plc first to sequence multiple human genomes using hand-held nanopore technology

The Wellcome Trust Centre for Human Genetics

Demonstrates potential for wide-scale whole-genome sequencing in humans using nanopore approaches

Oxford, UK, December 2, 2016: Oxford University’s Wellcome Trust Centre for Human Genetics (WTCHG) and the leading genome analytics company Genomics plc today announced the first sequencing and analysis of multiple human genomes using nanopore technology. The announcement, made on Thursday at the Oxford Nanopore Community Meeting in New York City, marks a major breakthrough in sequencing technology in opening up the potential of wide-scale whole-genome sequencing in humans using nanopore approaches.

Today’s announcement raises the possibility of a major change to both the economics and the science of DNA sequencing. Researchers at the WTCHG and Genomics plc used the MinION sequencer developed by Oxford Nanopore Technologies. The portable MinION is a hand-held device about the size of a Mars bar, and is powered by a laptop computer to which it connects via a USB port. It is available for $1,000 plus the cost of consumables. While nanopore sequencing has been available for two years, it has previously only been practicable to apply it to relatively small genomes or regions of DNA, such as the much smaller genomes of viruses and bacteria. Recent upgrades to the technology have now made it possible for researchers to conduct larger-scale studies such as sequencing complete human genomes by using multiple MinIONs.

A key strength of nanopore sequencing is that reads can be much longer than is possible with other scalable sequencing technologies. Longer reads offer significant advantages in human genome sequencing, enabling researchers to obtain good sequence data from certain biologically important regions of the genome which are difficult to study using existing sequencing technologies. The long reads also appear to make it easier to detect large structural changes in individual genomes.

The WTCHG and Genomics team sequenced a standard human reference sample, NA12878. In addition, in collaboration with the NIHR Oxford Biomedical Research Centre, they sequenced the DNA from a clinical patient.

Dr Rory Bowden, Deputy Head of High-Throughput Genomics at the WTCHG, and one of the leaders of the project, said: “It is a significant breakthrough to sequence multiple human genomes with nanopore technology. Moving forward, the idea that there will be alternative technologies with new properties in this space will be very appealing to researchers and to clinical geneticists.”

Professor Michael Simpson, Co-Head of Science at Genomics plc, another project leader, said: “It is particularly encouraging to show that nanopore sequencing works for routine clinical samples, where the amount and quality of DNA available for sequencing may be constrained. Further, in the clinical sample, the long reads provided by nanopore technology were critical in confirming the genetic changes responsible for the patient’s condition.”

Professor Peter Donnelly, Director of the WTCHG and a Founder and Director of Genomics plc, said: “The WTCHG were one of the pioneers of whole-genome sequencing in clinical medicine. We are delighted to be able to work with nanopore technology to sequence and analyse a reference and a clinical human genome, and to explore the potential for large-scale human sequencing using nanopore approaches.”
phone +44 (0)1865 287500
email info@well.ox.ac.uk
web www.well.ox.ac.uk
email The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.
More info >>


White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

Industry Events

Clinical Trial Supply Forum 2018

22-24 January 2018, London, UK

In the constantly changing environment of Clinical Trial Supply, cost efficiency, end to end visibility, logistics and managing complex pipelines are STILL crucial elements that need addressing!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement